Why we invested?
At MatchPlay, we invest in companies that don't just improve workflows, but redefine how critical systems operate.
Clinical trials are one of the most important yet structurally inefficient systems in healthcare. The numbers make this concrete: drug approval takes 8 to 9 years and costs over $2.5 billion, with a 90% failure rate. Meanwhile, 90% of trials are conducted in just 10% of the world, and 90% of known rare diseases have no approved treatments. The infrastructure problem is not incidental. It is central to why medicine moves so slowly.
The team
Jeeva is led by Harsha Rajasimha, Ph.D., whose background spans the NIH, FDA, NTT DATA, and Virginia Tech. He has built a team and advisory board that collectively brings over 150 years of combined expertise across biopharma, CROs, clinical sites, and medtech.
What stood out early was not just domain depth, but clarity of diagnosis. The team understands that the problem is not a lack of tools. It is that fragmented systems force decisions to be made manually, often reactively, across sponsors, sites, and patients who have no shared infrastructure. That insight shapes everything about how Jeeva is built.
Our perspective
The CRO market alone exceeds $80 billion globally. Yet much of that value is tied to managing complexity, not eliminating it.
The industry tried to solve this with more software, stitching together 15 or more point solutions in a regulated environment. It made the problem worse. Integrating those fragmented tools costs the industry over $4 billion a year. Sponsors, CROs, and sites still operate across disconnected systems where execution depends on manual coordination, and decisions are delayed, inconsistent, and error-prone.
This is not a tooling gap. It is an infrastructure failure.
What convinced us
Jeeva is not adding another layer to the stack. It is replacing the stack.
The platform unifies patient recruitment, randomization, informed consent, clinical trial management, electronic data capture, patient engagement, and decentralized trial capabilities in a single FDA-ready system that can be configured in under four weeks. Where incumbents like Veeva, Medidata, and traditional CROs monetize complexity, Jeeva removes it.
The business model reinforces this: clients are billed per participant per month, and only for actually enrolled participants. It is a pricing structure that aligns Jeeva's incentives directly with client outcomes.
What reinforced our conviction was the evidence from customers already using the platform:
- One client reduced costs by 70% and cut staff time by 30%
- Another saved 80% on costs with equivalent time savings
- A clinical professor replaced three separate tools with Jeeva's unified platform, saving 67% on costs, 50% on time, and reducing operational burden by 75%
These are not edge cases. They are consistent outcomes across 20+ clients, with zero reported attrition.
The platform has processed over 1 million data points across 25+ trials, with more than 26,000 users and patients on the system.
Why now?
Decentralized and hybrid trials are becoming the default. But without the right infrastructure, they increase complexity instead of solving it.
At the same time, the industry is under compounding pressure: reduce time-to-market, control costs, meet regulatory standards, and broaden patient participation beyond the 10% of the world where 90% of trials currently happen.
These forces converge on a single outcome: a unified execution layer is not optional. It is inevitable.
Our conviction
The next generation of clinical trials will be defined by platforms that eliminate fragmentation and reduce dependence on manual coordination. Over time, those platforms become the system of record, not just for how trials are managed, but for how drugs reach patients.
Jeeva is not building another tool for clinical trials.
It is building the system that clinical trials will run on.
